Get started
Author

Austin Speier

ORCID: 0000-0002-4260-7172
Observed ORCID: 0000-0002-4260-7172
OpenAlex ID: A5093849874
A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study)
2025 · Brian Rothman, Mary Slomkowski, et al. · Journal of Affective Disorders · 17
Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study
2024 · Brian Rothman, Mary Slomkowski, et al. · JMIR Research Protocols · 11
Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial
2025 · Shaheen E Lakhan, Cornelia Dorner-Ciossek, et al. · JMIR Research Protocols · 6
PDF
Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine prevention
2026 · Shaheen E. Lakhan, Mariya Petrova, et al. · npj Digital Medicine · 2
PDF
A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia: A Randomized Clinical Trial
2026 · Abhishek Pratap, Shaheen E. Lakhan, et al. · JAMA Network Open · 1
Supporting the Primary Outcomes of the Mirai Trial for the Adjunctive Digital Therapeutic Rejoyn (CT-152) in the Treatment of Major Depressive Disorder: Meaningful Change Analysis in the Montgomery-Åsberg Depression Rating Scale
2026 · Stacie Hudgens, Intan Purnajo, et al. · JMIR Formative Research
Works count: 6
Citation count: 37
H-index: 3
I10-index: 2
Year
Topic
Type